December 2025 clinical trial highlights
Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).
Each month, we'll highlight a few of the many trials enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with IPF
Zinc and Nicotinamide Riboside for IPF
- Study ID: NCT06567717
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Cedars-Sinai Medical Center
- Study Contact: Study Coordinator (310.423.8474; GroupLungResearch@cshs.org); Tanzira Zaman, MD (310.423.6303; Tanzira.Zaman@cshs.org)
Seeking participants with PH-ILD
A Study of Mosliciguat in PH-ILD
- Study ID: NCT06635850
- Trial Phase: Phase 2
- Intervention: Inhaled drug
- Sponsor: Pulmovant, Inc.
- Study Contact: 919.462.1310, clinicaltrials@pulmovant.com
Seeking participants with IPF
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
- Study ID: NCT05195918
- Trial Phase: Phase 1
- Intervention: Oral drug
- Sponsor: Hal Chapman
- Study Contact: Ying Wei, MD (415.514.1209; ying.wei@ucsf.edu); Harold Chapman, MD (415.514.1210; hal.chapman@ucsf.edu)
Seeking participants with hypersensitivity pneumonitis
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
- Study ID: NCT06811389
- Intervention: Observational
- Sponsor: Weill Medical College of Cornell University
- Study Contact: Anna Tharakan, BS (646.962.8130; ant4034@med.cornell.edu); Alicia Morris (646.962.2741; ajm2017@med.cornell.edu)
When Gretchen's doctor found honeycombing in her lungs, she knew what it meant; she had watched her younger sister die from PF less than a year earlier. Thanks to her pulmonologist's careful monitoring, Gretchen was diagnosed early.
As she listened to her doctor describe anti-fibrotic medications that could potentially slow down the progression of PF, Gretchen knew she didn’t need time to think it over. She was willing to do whatever she could to fight the disease. Even though there have been many bumps in the road, Gretchen has been able to manage the disease with the help of medication, diet, exercise, a supportive community, and her experience in clinical trials. Today, she shares what she has learned along the way as a Pulmonary Fibrosis Foundation Ambassador.
For a comprehensive overview of PF, explore the PF Basics: Info for Newly Diagnosed Patients.
FDA Approves Nerandomilast for Progressive Pulmonary Fibrosis
In December 2025, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s nerandomilast (JASCAYD) for the treatment of progressive pulmonary fibrosis (PPF) in adults. This decision follows the FDA’s October 7, 2025, approval of nerandomilast for IPF. Together, these approvals mark meaningful milestones for people living with PF, expanding treatment options and reinforcing progress in care for both IPF and PPF. |
PFF Summit 2025
At the PFF Summit in November 2025, the PFF celebrated 25 years of funding groundbreaking research, uniting patients and professionals, and lighting the path toward a cure, while also underscoring the Foundation's enduring legacy and its 2025-2030 strategic plan, “The PFF Is Me.” Across the conference’s three days, the PFF held sessions on the newest treatments and latest research in PF and ILD and provided opportunities for leading experts and members of the PF and ILD community to connect.
A few highlights from the conference:
- Day 1: The first day consisted of the Welcome Reception and Poster Presentation, where Summit attendees could learn about innovations from industry representatives, medical centers, and patient advocacy organizations.
- Day 2: Highlights included the Keynote Address by Dr. Karen Mancera-Cuevas, "Beyond representation: Building equitable clinical trials for all populations," and the Dine and Delight Networking Night hosted by Broadway star and PFF Board member, Julie Halston.
- Day 3: The final day held the Keynote Address by James Fraser, PhD, "Unlocking the future: How Artificial Intelligence (AI) is transforming pre-clinical drug discovery."
We sincerely appreciate the PF and ILD community for coming together to make this possible. We look forward to seeing you all again for the next Summit in 2027 at Bellevue, Washington.
PFF’s Strategic 5-Year Plan
The November 2025 Rare Disease Advisor press release covered the launch of the PFF’s 2025-2030 strategic plan. The plan, based on input from over 350 stakeholders, aims to accelerate research, expand care, improve patient lives, and build community. Key goals include enrolling an additional 6,000 participants in the PFF Community Registry, supporting 25 more scientific publications, expanding the PFF Care Center Network into five new states, and boosting PFF Help Center usage by 20%. Read the full strategic plan to learn about these key initiatives and more.
Lung Transplant Rejection Study
Northwestern Medicine recently published a study regarding chronic lung-transplant rejection, which is the leading cause of death after the first year of transplantation and affects over 50% of recipients within five years. Currently, there are no effective treatments besides re-transplantation. The research, led by Dr. Ankit Bharat from Northwestern Medicine Canning Thoracic Institute, provides the first comprehensive roadmap by identifying that abnormal donor and recipient cells communicate in harmful ways to drive lung damage and rejection. Researchers found a cell type marked by KRT17 and KRT5—which has already been identified as a factor to develop scarring in several lung diseases, including IPF, COPD, and COVID-19–related lung damage—contributes to scar formation in chronic lung allograft dysfunction (CLAD). These insights may open the door to new treatments for transplant rejection, potentially including the use of existing antifibrotic drugs like nintedanib and pirfenidone. |
|
If you have any questions or comments about this newsletter, please email partnerships@